HOME OF GUANGDONG LUNG CANCER INSTITUTE (GLCI) · GLOBAL LUNG CANCER RESEARCH BEACON
Guangdong Provincial People's Hospital (GDPH)
Founded in 1946, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences) is one of South China’s largest and most distinguished academic medical centers. Affiliated with Southern Medical University and Sun Yat-sen University, the hospital is internationally celebrated as the home of the world-famous Guangdong Lung Cancer Institute (GLCI).
Founded and led by internationally renowned thoracic oncologist Prof. Wu Yilong (recipient of the IASLC Joseph Cullen Award), GLCI has led landmark clinical trials that established standard first-line targeted therapies (EGFR, ALK, ROS1, RET, MET) and perioperative immunotherapies for lung cancer globally.
FOUR CLINICAL EXCELLENCE PILLARS
Core Thoracic & Molecular Oncology Capabilities
Global leadership in molecular targeted therapies, uniportal VATS surgery, and multi-system cardio-oncology safety.
Targeted Molecular Therapy
International pioneer in targeting rare EGFR exon 20 insertions, HER2 mutations, KRAS G12C, and fusion oncogenes.
Uniportal VATS Surgery
Ultra-minimally invasive uniportal VATS anatomical segmentectomy preserving healthy lung reserve and rapid recovery.
Perioperative Immunotherapy
Landmark protocols combining neoadjuvant and adjuvant immunotherapy to eradicate micro-metastases and extend cure.
Cardio-Oncology Center
Asia’s leading cardio-oncology program protecting cardiovascular health during intensive cancer chemotherapy and immunotherapy.
WORLD-RENOWNED LUNG CANCER MASTERMINDS
Academic Faculty & Department Leadership
Steered by past presidents of the Chinese Society of Clinical Oncology and IASLC award recipients.
Prof. Wu Yilong, MD, PhD
Global pioneer in precision lung cancer medicine whose landmark trials established EGFR tyrosine kinase inhibitors as standard first-line treatment worldwide. Prof. Wu directs international clinical trial networks.
Prof. Zhou Qing, MD, PhD
Leading investigator in overcoming resistance to 3rd-generation EGFR inhibitors and evaluating novel antibody-drug conjugates (ADCs) for non-small cell lung cancer.
CASE INTAKE & SPECIALIST TRIAGE
Initiate Your Case Review with GDPH / Lung Cancer Institute
Submit your contact details, confirmed diagnosis, and main question below. You do not need to upload any medical files at this stage. Our clinical coordinator will contact you directly within 24–48 hours to discuss potential GDPH thoracic and oncological pathways in China and assist you in gathering the specific medical records needed for expert hospital review.
PATIENT INQUIRIES
Frequently Asked Questions About GDPH / Lung Cancer Institute
Key clinical, logistical, and technical facts regarding international admissions, surgical evaluations, advanced technology access, and personalized care coordination at GDPH / Lung Cancer Institute.
GLCI leads international trials for novel 4th-generation EGFR TKIs, bispecific antibodies (e.g., EGFR/c-MET), and next-generation antibody-drug conjugates (ADCs), identifying actionable resistance bypass pathways via liquid ctDNA biopsy.
GLCI utilizes 3D computational CT reconstruction and ultra-minimally invasive uniportal VATS segmentectomy, achieving complete oncologic resection while preserving maximum lung tissue and function.
Yes. GLCI’s high-throughput laboratory provides comprehensive NGS panel testing on tissue biopsies and liquid ctDNA within 5 business days of sample receipt.
Many advanced targeted drugs and immunotherapies carry risks of myocarditis or heart failure. GDPH’s cardio-oncology team provides continuous monitoring, ensuring aggressive cancer treatments can be safely maintained.
MODERN CLINICAL INFRASTRUCTURE
Strategic Multi-Campus Setup & International Transit
Modern clinical hubs designed for seamless aeromedical transport, multidisciplinary conferences, and dedicated international inpatient care.
GDPH Yuexiu Main Campus
106 Zhongshan 2nd Road, Yuexiu District, Guangzhou
Primary clinical headquarters housing the Guangdong Lung Cancer Institute, thoracic surgical wards, and VIP inpatient suites.
GDPH Baiyun International Campus
Baiyun High-Tech Medical Zone, Guangzhou
Modern research hospital featuring advanced oncology pavilions and convenient transit to Baiyun International Airport.